Evidence map›Paper›PMID 26393919›Full record

ArticlePloS one2015

Prolonged Subcutaneous Administration of Oxytocin Accelerates Angiotensin II-Induced Hypertension and Renal Damage in Male Rats.

James Phie, Nagaraja Haleagrahara, Patricia Newton, Constantin Constantinoiu, Zoltan Sarnyai, Lisa Chilton, Robert Kinobe

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Sex differences in cardiovascular actions of the renin-angiotensin system.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2020
    Review
  7. Review
  8. Article
  9. Review
  10. Oxytocin and cancer: An emerging link.World journal of clinical oncology · 2018
    Review
  11. Sex dimorphism in ANGII-mediated crosstalk between ACE2 and ACE in diabetic nephropathy.Laboratory investigation; a journal of technical methods and pathology · 2018
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

James PhieCollege of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Queensland 4811 Australia.
Nagaraja HaleagraharaCollege of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Queensland 4811 Australia.
Patricia NewtonCollege of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Queensland 4811 Australia.
Constantin ConstantinoiuCollege of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Queensland 4811 Australia.
Zoltan SarnyaiCollege of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Queensland 4811 Australia; Centre for Biodiscovery & Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Townsville Queensland 4811, Australia.
Lisa ChiltonCollege of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Queensland 4811 Australia.
Robert KinobeCollege of Public Health, Medical & Veterinary Sciences, James Cook University, Townsville, Queensland 4811 Australia; Centre for Biodiscovery & Molecular Development of Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Townsville Queensland 4811, Australia.
James Cook University · AUAustralian Institute of Tropical Health and Medicine · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxytocin and its receptor are synthesised in the heart and blood vessels but effects of chronic activation of this peripheral oxytocinergic system on cardiovascular function are not known. In acute studies, systemic administration of low dose oxytocin exerted a protective, preconditioning effect in experimental models of myocardial ischemia and infarction. In this study, we investigated the effects of chronic administration of low dose oxytocin following angiotensin II-induced hypertension, cardiac hypertrophy and renal damage. Angiotensin II (40 μg/Kg/h) only, oxytocin only (20 or 100 ng/Kg/h), or angiotensin II combined with oxytocin (20 or 100 ng/Kg/h) were infused subcutaneously in adult male Sprague-Dawley rats for 28 days. At day 7, oxytocin or angiotensin-II only did not change hemodynamic parameters, but animals that received a combination of oxytocin and angiotensin-II had significantly elevated systolic, diastolic and mean arterial pressure compared to controls (P < 0.01). Hemodynamic changes were accompanied by significant left ventricular cardiac hypertrophy and renal damage at day 28 in animals treated with angiotensin II (P < 0.05) or both oxytocin and angiotensin II, compared to controls (P < 0.01). Prolonged oxytocin administration did not affect plasma concentrations of renin and atrial natriuretic peptide, but was associated with the activation of calcium-dependent protein phosphatase calcineurin, a canonical signalling mechanism in pressure overload-induced cardiovascular disease. These data demonstrate that oxytocin accelerated angiotensin-II induced hypertension and end-organ renal damage, suggesting caution should be exercised in the chronic use of oxytocin in individuals with hypertension.

Indexed as

Angiotensin IIAnimalsAtrial Natriuretic FactorCalcineurinCardiomegalyHypertensionInjections, SubcutaneousKidneyMaleOxytocinRatsRats, Sprague-DawleyReninAngiotensin IIAtrial Natriuretic FactorCalcineurinOxytocinRenin

Identifiers

PMID26393919
PMCPMC4579129
OpenAlexW2253996488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.